JPMorgan upgraded Camp4 Therapeutics to Overweight from Neutral with a price target of $9, up from $5. The shares are undervalued on the potential for CMP-002 in SYNGAP1-related disorder, the analyst tells investors in a research note. The firm also believes Camp4's September research and development day should highlight its potential longer-term pipeline drives. The company CAMP4 has completed good laboratory practice toxicology studies for CMP-002 and received regulatory feedback from several jurisdictions, adds JPMorgan.
